nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP2C18—malignant glioma	0.419	0.574	CbGaD
Methadone—CYP2B6—malignant glioma	0.311	0.426	CbGaD
Methadone—CYP1A2—Carmustine—malignant glioma	0.0635	0.569	CbGbCtD
Methadone—CYP3A4—Temozolomide—malignant glioma	0.048	0.43	CbGbCtD
Methadone—HTR3A—fourth ventricle—malignant glioma	0.0126	0.363	CbGeAlD
Methadone—OPRM1—telencephalic ventricle—malignant glioma	0.00334	0.0963	CbGeAlD
Methadone—Intracranial pressure increased—Carmustine—malignant glioma	0.00174	0.0715	CcSEcCtD
Methadone—GRIN3A—telencephalon—malignant glioma	0.00167	0.0481	CbGeAlD
Methadone—OPRD1—telencephalon—malignant glioma	0.00118	0.0339	CbGeAlD
Methadone—Lung disorder—Temozolomide—malignant glioma	0.000994	0.0408	CcSEcCtD
Methadone—HTR3A—brainstem—malignant glioma	0.000986	0.0284	CbGeAlD
Methadone—GRIN3A—central nervous system—malignant glioma	0.000949	0.0273	CbGeAlD
Methadone—OPRM1—brainstem—malignant glioma	0.000904	0.0261	CbGeAlD
Methadone—HTR3A—telencephalon—malignant glioma	0.000875	0.0252	CbGeAlD
Methadone—OPRM1—telencephalon—malignant glioma	0.000802	0.0231	CbGeAlD
Methadone—Amenorrhoea—Temozolomide—malignant glioma	0.000801	0.0328	CcSEcCtD
Methadone—Drug interaction—Carmustine—malignant glioma	0.000785	0.0322	CcSEcCtD
Methadone—GRIN3A—brain—malignant glioma	0.000753	0.0217	CbGeAlD
Methadone—OPRD1—central nervous system—malignant glioma	0.000668	0.0193	CbGeAlD
Methadone—Benzphetamine—POR—malignant glioma	0.000664	0.136	CrCbGaD
Methadone—OPRK1—central nervous system—malignant glioma	0.000641	0.0185	CbGeAlD
Methadone—OPRK1—cerebellum—malignant glioma	0.000626	0.0181	CbGeAlD
Methadone—Phlebitis—Carmustine—malignant glioma	0.000614	0.0252	CcSEcCtD
Methadone—Swelling—Carmustine—malignant glioma	0.000599	0.0246	CcSEcCtD
Methadone—OPRM1—midbrain—malignant glioma	0.000576	0.0166	CbGeAlD
Methadone—OPRM1—spinal cord—malignant glioma	0.000562	0.0162	CbGeAlD
Methadone—OPRD1—brain—malignant glioma	0.000531	0.0153	CbGeAlD
Methadone—OPRK1—brain—malignant glioma	0.000509	0.0147	CbGeAlD
Methadone—HTR3A—central nervous system—malignant glioma	0.000497	0.0143	CbGeAlD
Methadone—Hypokalaemia—Carmustine—malignant glioma	0.000481	0.0197	CcSEcCtD
Methadone—ABCB1—blood vessel—malignant glioma	0.000477	0.0137	CbGeAlD
Methadone—Hypokalaemia—Temozolomide—malignant glioma	0.000465	0.0191	CcSEcCtD
Methadone—OPRM1—central nervous system—malignant glioma	0.000456	0.0131	CbGeAlD
Methadone—Sweating increased—Temozolomide—malignant glioma	0.00043	0.0176	CcSEcCtD
Methadone—Weight increased—Temozolomide—malignant glioma	0.000402	0.0165	CcSEcCtD
Methadone—Weight decreased—Temozolomide—malignant glioma	0.000399	0.0164	CcSEcCtD
Methadone—HTR3A—brain—malignant glioma	0.000395	0.0114	CbGeAlD
Methadone—CYP19A1—central nervous system—malignant glioma	0.000383	0.011	CbGeAlD
Methadone—Hallucination—Carmustine—malignant glioma	0.000364	0.0149	CcSEcCtD
Methadone—CYP2D6—brainstem—malignant glioma	0.000362	0.0104	CbGeAlD
Methadone—OPRM1—brain—malignant glioma	0.000362	0.0104	CbGeAlD
Methadone—Visual impairment—Carmustine—malignant glioma	0.000352	0.0145	CcSEcCtD
Methadone—Hallucination—Temozolomide—malignant glioma	0.000352	0.0144	CcSEcCtD
Methadone—Oxaprozin—PTGS1—malignant glioma	0.000348	0.0713	CrCbGaD
Methadone—Visual impairment—Temozolomide—malignant glioma	0.000341	0.014	CcSEcCtD
Methadone—Flushing—Carmustine—malignant glioma	0.000339	0.0139	CcSEcCtD
Methadone—Flushing—Temozolomide—malignant glioma	0.000328	0.0135	CcSEcCtD
Methadone—Arrhythmia—Carmustine—malignant glioma	0.000327	0.0134	CcSEcCtD
Methadone—CYP2D6—telencephalon—malignant glioma	0.000322	0.00927	CbGeAlD
Methadone—Erythema—Carmustine—malignant glioma	0.000318	0.0131	CcSEcCtD
Methadone—Chills—Temozolomide—malignant glioma	0.000317	0.013	CcSEcCtD
Methadone—Clotrimazole—CYP2B6—malignant glioma	0.000313	0.0642	CrCbGaD
Methadone—Erythema—Temozolomide—malignant glioma	0.000308	0.0126	CcSEcCtD
Methadone—CYP19A1—brain—malignant glioma	0.000304	0.00877	CbGeAlD
Methadone—Tremor—Carmustine—malignant glioma	0.000298	0.0122	CcSEcCtD
Methadone—Ethopropazine—BCHE—malignant glioma	0.000298	0.0612	CrCbGaD
Methadone—Agitation—Carmustine—malignant glioma	0.000293	0.012	CcSEcCtD
Methadone—Tremor—Temozolomide—malignant glioma	0.000288	0.0118	CcSEcCtD
Methadone—ABCB1—embryo—malignant glioma	0.000284	0.0082	CbGeAlD
Methadone—Agitation—Temozolomide—malignant glioma	0.000283	0.0116	CcSEcCtD
Methadone—Vertigo—Temozolomide—malignant glioma	0.000276	0.0113	CcSEcCtD
Methadone—Convulsion—Carmustine—malignant glioma	0.000276	0.0113	CcSEcCtD
Methadone—Modafinil—CYP2B6—malignant glioma	0.000273	0.0561	CrCbGaD
Methadone—Palpitations—Temozolomide—malignant glioma	0.000272	0.0111	CcSEcCtD
Methadone—Anxiety—Carmustine—malignant glioma	0.00027	0.0111	CcSEcCtD
Methadone—Convulsion—Temozolomide—malignant glioma	0.000267	0.0109	CcSEcCtD
Methadone—Confusional state—Carmustine—malignant glioma	0.000262	0.0107	CcSEcCtD
Methadone—Anxiety—Temozolomide—malignant glioma	0.000261	0.0107	CcSEcCtD
Methadone—Oedema—Carmustine—malignant glioma	0.00026	0.0107	CcSEcCtD
Methadone—Loperamide—CYP2B6—malignant glioma	0.000258	0.0529	CrCbGaD
Methadone—Dry mouth—Temozolomide—malignant glioma	0.000256	0.0105	CcSEcCtD
Methadone—Diphenhydramine—CYP2C18—malignant glioma	0.000256	0.0525	CrCbGaD
Methadone—Thrombocytopenia—Carmustine—malignant glioma	0.000254	0.0104	CcSEcCtD
Methadone—Tachycardia—Carmustine—malignant glioma	0.000254	0.0104	CcSEcCtD
Methadone—Confusional state—Temozolomide—malignant glioma	0.000253	0.0104	CcSEcCtD
Methadone—ABCB1—retina—malignant glioma	0.000251	0.00725	CbGeAlD
Methadone—Anaphylactic shock—Temozolomide—malignant glioma	0.000251	0.0103	CcSEcCtD
Methadone—Oedema—Temozolomide—malignant glioma	0.000251	0.0103	CcSEcCtD
Methadone—Anorexia—Carmustine—malignant glioma	0.000248	0.0102	CcSEcCtD
Methadone—CYP2B6—central nervous system—malignant glioma	0.000246	0.00709	CbGeAlD
Methadone—Thrombocytopenia—Temozolomide—malignant glioma	0.000246	0.0101	CcSEcCtD
Methadone—Hypotension—Carmustine—malignant glioma	0.000243	0.00996	CcSEcCtD
Methadone—Hyperhidrosis—Temozolomide—malignant glioma	0.000243	0.00995	CcSEcCtD
Methadone—Anorexia—Temozolomide—malignant glioma	0.000239	0.00982	CcSEcCtD
Methadone—Benzphetamine—CYP2B6—malignant glioma	0.000237	0.0487	CrCbGaD
Methadone—Insomnia—Carmustine—malignant glioma	0.000235	0.00964	CcSEcCtD
Methadone—Modafinil—SLC6A3—malignant glioma	0.000233	0.0478	CrCbGaD
Methadone—ABCB1—telencephalon—malignant glioma	0.000231	0.00667	CbGeAlD
Methadone—Somnolence—Carmustine—malignant glioma	0.000231	0.00947	CcSEcCtD
Methadone—Phenylbutazone—PTGS1—malignant glioma	0.00023	0.0471	CrCbGaD
Methadone—Insomnia—Temozolomide—malignant glioma	0.000227	0.00931	CcSEcCtD
Methadone—Decreased appetite—Carmustine—malignant glioma	0.000226	0.00926	CcSEcCtD
Methadone—Somnolence—Temozolomide—malignant glioma	0.000223	0.00915	CcSEcCtD
Methadone—Pain—Carmustine—malignant glioma	0.000222	0.00911	CcSEcCtD
Methadone—Constipation—Carmustine—malignant glioma	0.000222	0.00911	CcSEcCtD
Methadone—Decreased appetite—Temozolomide—malignant glioma	0.000218	0.00895	CcSEcCtD
Methadone—CYP2C8—brain—malignant glioma	0.000218	0.00628	CbGeAlD
Methadone—Pain—Temozolomide—malignant glioma	0.000215	0.00881	CcSEcCtD
Methadone—Constipation—Temozolomide—malignant glioma	0.000215	0.00881	CcSEcCtD
Methadone—Feeling abnormal—Carmustine—malignant glioma	0.000214	0.00878	CcSEcCtD
Methadone—Gastrointestinal pain—Carmustine—malignant glioma	0.000212	0.00871	CcSEcCtD
Methadone—Feeling abnormal—Temozolomide—malignant glioma	0.000207	0.00849	CcSEcCtD
Methadone—Body temperature increased—Carmustine—malignant glioma	0.000205	0.00842	CcSEcCtD
Methadone—Abdominal pain—Carmustine—malignant glioma	0.000205	0.00842	CcSEcCtD
Methadone—Gastrointestinal pain—Temozolomide—malignant glioma	0.000205	0.00842	CcSEcCtD
Methadone—Benzphetamine—SLC6A3—malignant glioma	0.000202	0.0415	CrCbGaD
Methadone—Atomoxetine—SLC6A3—malignant glioma	0.0002	0.0411	CrCbGaD
Methadone—Urticaria—Temozolomide—malignant glioma	0.000199	0.00818	CcSEcCtD
Methadone—Oxaprozin—PTGS2—malignant glioma	0.000199	0.0408	CrCbGaD
Methadone—Abdominal pain—Temozolomide—malignant glioma	0.000198	0.00814	CcSEcCtD
Methadone—Body temperature increased—Temozolomide—malignant glioma	0.000198	0.00814	CcSEcCtD
Methadone—CYP2B6—brain—malignant glioma	0.000195	0.00563	CbGeAlD
Methadone—Hypersensitivity—Carmustine—malignant glioma	0.000191	0.00785	CcSEcCtD
Methadone—Diphenhydramine—CYP2B6—malignant glioma	0.00019	0.039	CrCbGaD
Methadone—Asthenia—Carmustine—malignant glioma	0.000186	0.00764	CcSEcCtD
Methadone—Promethazine—CYP2B6—malignant glioma	0.000186	0.0382	CrCbGaD
Methadone—CYP3A4—central nervous system—malignant glioma	0.000186	0.00535	CbGeAlD
Methadone—Hypersensitivity—Temozolomide—malignant glioma	0.000185	0.00759	CcSEcCtD
Methadone—Tamoxifen—CYP2B6—malignant glioma	0.000185	0.038	CrCbGaD
Methadone—CYP2D6—central nervous system—malignant glioma	0.000183	0.00527	CbGeAlD
Methadone—ABCB1—medulla oblongata—malignant glioma	0.000182	0.00524	CbGeAlD
Methadone—Asthenia—Temozolomide—malignant glioma	0.00018	0.00739	CcSEcCtD
Methadone—Orphenadrine—CYP2B6—malignant glioma	0.00018	0.0369	CrCbGaD
Methadone—CYP2D6—cerebellum—malignant glioma	0.000179	0.00515	CbGeAlD
Methadone—Diarrhoea—Carmustine—malignant glioma	0.000178	0.00729	CcSEcCtD
Methadone—Pruritus—Temozolomide—malignant glioma	0.000178	0.00728	CcSEcCtD
Methadone—Dizziness—Carmustine—malignant glioma	0.000172	0.00705	CcSEcCtD
Methadone—Diarrhoea—Temozolomide—malignant glioma	0.000172	0.00705	CcSEcCtD
Methadone—ABCB1—midbrain—malignant glioma	0.000166	0.00479	CbGeAlD
Methadone—Dizziness—Temozolomide—malignant glioma	0.000166	0.00681	CcSEcCtD
Methadone—Vomiting—Carmustine—malignant glioma	0.000165	0.00677	CcSEcCtD
Methadone—Trimipramine—SLC6A3—malignant glioma	0.000165	0.0338	CrCbGaD
Methadone—Rash—Carmustine—malignant glioma	0.000164	0.00672	CcSEcCtD
Methadone—Dermatitis—Carmustine—malignant glioma	0.000164	0.00671	CcSEcCtD
Methadone—Headache—Carmustine—malignant glioma	0.000163	0.00668	CcSEcCtD
Methadone—ABCB1—spinal cord—malignant glioma	0.000162	0.00467	CbGeAlD
Methadone—Vomiting—Temozolomide—malignant glioma	0.00016	0.00655	CcSEcCtD
Methadone—Rash—Temozolomide—malignant glioma	0.000158	0.00649	CcSEcCtD
Methadone—Dermatitis—Temozolomide—malignant glioma	0.000158	0.00649	CcSEcCtD
Methadone—Headache—Temozolomide—malignant glioma	0.000157	0.00645	CcSEcCtD
Methadone—Nausea—Carmustine—malignant glioma	0.000154	0.00633	CcSEcCtD
Methadone—Nausea—Temozolomide—malignant glioma	0.000149	0.00612	CcSEcCtD
Methadone—CYP2D6—brain—malignant glioma	0.000145	0.00418	CbGeAlD
Methadone—ABCB1—central nervous system—malignant glioma	0.000131	0.00379	CbGeAlD
Methadone—Phenylbutazone—PTGS2—malignant glioma	0.000131	0.027	CrCbGaD
Methadone—ABCB1—cerebellum—malignant glioma	0.000129	0.0037	CbGeAlD
Methadone—Diphenhydramine—PTGS1—malignant glioma	0.000125	0.0257	CrCbGaD
Methadone—ABCB1—brain—malignant glioma	0.000104	0.00301	CbGeAlD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.39e-06	8.91e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CAV1—malignant glioma	8.39e-06	8.91e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GSTP1—malignant glioma	8.33e-06	8.85e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KDR—malignant glioma	8.3e-06	8.81e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CAT—malignant glioma	8.29e-06	8.81e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT2—malignant glioma	8.27e-06	8.79e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—malignant glioma	8.24e-06	8.75e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—PIK3CA—malignant glioma	8.15e-06	8.66e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MDM2—malignant glioma	8.12e-06	8.63e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CAT—malignant glioma	8.1e-06	8.61e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RAF1—malignant glioma	8.09e-06	8.6e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—BCHE—malignant glioma	8.09e-06	8.6e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—ERBB2—malignant glioma	8.01e-06	8.51e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS1—malignant glioma	8e-06	8.5e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—SLC5A5—malignant glioma	7.99e-06	8.49e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—F2—malignant glioma	7.98e-06	8.48e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—FN1—malignant glioma	7.98e-06	8.48e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP2B6—malignant glioma	7.96e-06	8.46e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CD—malignant glioma	7.96e-06	8.45e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CD—malignant glioma	7.95e-06	8.44e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS1—malignant glioma	7.93e-06	8.43e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	7.91e-06	8.4e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CB—malignant glioma	7.9e-06	8.39e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—BCHE—malignant glioma	7.9e-06	8.39e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—BAD—malignant glioma	7.89e-06	8.38e-05	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—PIK3CA—malignant glioma	7.87e-06	8.36e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CG—malignant glioma	7.86e-06	8.35e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NCOR1—malignant glioma	7.83e-06	8.32e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTEN—malignant glioma	7.83e-06	8.32e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NOTCH1—malignant glioma	7.81e-06	8.3e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—SLC5A5—malignant glioma	7.8e-06	8.29e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—KRAS—malignant glioma	7.78e-06	8.27e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	7.68e-06	8.16e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CD80—malignant glioma	7.66e-06	8.13e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NCOR1—malignant glioma	7.65e-06	8.13e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—APC—malignant glioma	7.64e-06	8.12e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CG—malignant glioma	7.64e-06	8.12e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—FGF2—malignant glioma	7.61e-06	8.09e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—malignant glioma	7.59e-06	8.07e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PPARG—malignant glioma	7.59e-06	8.06e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	7.56e-06	8.03e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGF—malignant glioma	7.55e-06	8.03e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTPN11—malignant glioma	7.51e-06	7.98e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	7.49e-06	7.96e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—BCHE—malignant glioma	7.44e-06	7.91e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	7.42e-06	7.88e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—BCHE—malignant glioma	7.38e-06	7.84e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—SLC5A5—malignant glioma	7.35e-06	7.81e-05	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AKT1—malignant glioma	7.33e-06	7.79e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.32e-06	7.77e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—SLC5A5—malignant glioma	7.29e-06	7.74e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—IDH1—malignant glioma	7.28e-06	7.74e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CASP3—malignant glioma	7.27e-06	7.72e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2—malignant glioma	7.26e-06	7.71e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTT1—malignant glioma	7.24e-06	7.69e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GSTP1—malignant glioma	7.21e-06	7.66e-05	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	7.18e-06	7.63e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—BRAF—malignant glioma	7.18e-06	7.63e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—PIK3CA—malignant glioma	7.15e-06	7.6e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MDM2—malignant glioma	7.12e-06	7.57e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RAF1—malignant glioma	7.1e-06	7.54e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SPHK1—malignant glioma	7.05e-06	7.49e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—ERBB2—malignant glioma	7.02e-06	7.46e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CAT—malignant glioma	7.02e-06	7.46e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT2—malignant glioma	6.99e-06	7.43e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—malignant glioma	6.96e-06	7.4e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CB—malignant glioma	6.94e-06	7.37e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CB—malignant glioma	6.93e-06	7.36e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CD—malignant glioma	6.91e-06	7.34e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CYP2C18—malignant glioma	6.91e-06	7.34e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	6.89e-06	7.32e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—malignant glioma	6.87e-06	7.3e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—malignant glioma	6.87e-06	7.3e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	6.83e-06	7.25e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTEN—malignant glioma	6.83e-06	7.25e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS1—malignant glioma	6.78e-06	7.2e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.76e-06	7.18e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CD—malignant glioma	6.72e-06	7.14e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AKT1—malignant glioma	6.66e-06	7.08e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—malignant glioma	6.66e-06	7.07e-05	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—PIK3CA—malignant glioma	6.65e-06	7.07e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NCOR1—malignant glioma	6.63e-06	7.04e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—KRAS—malignant glioma	6.58e-06	6.99e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.53e-06	6.94e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTP1—malignant glioma	6.44e-06	6.84e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—FGF2—malignant glioma	6.43e-06	6.83e-05	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AKT1—malignant glioma	6.43e-06	6.83e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CAV1—malignant glioma	6.38e-06	6.78e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CASP3—malignant glioma	6.37e-06	6.77e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2—malignant glioma	6.36e-06	6.76e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—BCHE—malignant glioma	6.3e-06	6.7e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTP1—malignant glioma	6.28e-06	6.68e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CAT—malignant glioma	6.26e-06	6.66e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CAV1—malignant glioma	6.24e-06	6.63e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SLC5A5—malignant glioma	6.23e-06	6.62e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—malignant glioma	6.17e-06	6.55e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CAT—malignant glioma	6.11e-06	6.5e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—malignant glioma	6.11e-06	6.49e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—PIK3CA—malignant glioma	6.04e-06	6.42e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CB—malignant glioma	6.02e-06	6.4e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—malignant glioma	6.02e-06	6.4e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MDM2—malignant glioma	6.02e-06	6.39e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RAF1—malignant glioma	6e-06	6.37e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTEN—malignant glioma	5.99e-06	6.37e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTEN—malignant glioma	5.99e-06	6.36e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—malignant glioma	5.97e-06	6.34e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.95e-06	6.33e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ERBB2—malignant glioma	5.93e-06	6.3e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTP1—malignant glioma	5.92e-06	6.29e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NCOR1—malignant glioma	5.92e-06	6.28e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.89e-06	6.26e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTP1—malignant glioma	5.87e-06	6.24e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CB—malignant glioma	5.86e-06	6.22e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AKT1—malignant glioma	5.84e-06	6.21e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.83e-06	6.2e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CG—malignant glioma	5.81e-06	6.18e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NCOR1—malignant glioma	5.77e-06	6.13e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CAT—malignant glioma	5.76e-06	6.12e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CAT—malignant glioma	5.71e-06	6.07e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CG—malignant glioma	5.68e-06	6.04e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MYC—malignant glioma	5.67e-06	6.03e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—malignant glioma	5.63e-06	5.98e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—malignant glioma	5.61e-06	5.96e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTT1—malignant glioma	5.58e-06	5.93e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—malignant glioma	5.55e-06	5.9e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PIK3CA—malignant glioma	5.52e-06	5.87e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—malignant glioma	5.48e-06	5.83e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NCOR1—malignant glioma	5.44e-06	5.78e-05	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AKT1—malignant glioma	5.44e-06	5.78e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—malignant glioma	5.41e-06	5.75e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CAV1—malignant glioma	5.4e-06	5.74e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NCOR1—malignant glioma	5.39e-06	5.73e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CASP3—malignant glioma	5.39e-06	5.72e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2—malignant glioma	5.38e-06	5.71e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—malignant glioma	5.35e-06	5.69e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KRAS—malignant glioma	5.24e-06	5.57e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS1—malignant glioma	5.23e-06	5.56e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTEN—malignant glioma	5.2e-06	5.53e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.16e-06	5.48e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CD—malignant glioma	5.11e-06	5.43e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—malignant glioma	5.09e-06	5.41e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	5.09e-06	5.41e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTEN—malignant glioma	5.06e-06	5.38e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTP1—malignant glioma	5.02e-06	5.33e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CD—malignant glioma	4.99e-06	5.31e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MYC—malignant glioma	4.98e-06	5.29e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AKT1—malignant glioma	4.94e-06	5.24e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CG—malignant glioma	4.92e-06	5.23e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CAT—malignant glioma	4.88e-06	5.19e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—malignant glioma	4.87e-06	5.17e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—BCHE—malignant glioma	4.87e-06	5.17e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CAV1—malignant glioma	4.82e-06	5.12e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CA—malignant glioma	4.82e-06	5.12e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC5A5—malignant glioma	4.81e-06	5.11e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—malignant glioma	4.75e-06	5.05e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CAV1—malignant glioma	4.71e-06	5e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—malignant glioma	4.66e-06	4.95e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NCOR1—malignant glioma	4.61e-06	4.9e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.61e-06	4.89e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KRAS—malignant glioma	4.6e-06	4.88e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—malignant glioma	4.57e-06	4.86e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—malignant glioma	4.53e-06	4.81e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AKT1—malignant glioma	4.51e-06	4.79e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CB—malignant glioma	4.45e-06	4.73e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CAV1—malignant glioma	4.44e-06	4.71e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—malignant glioma	4.41e-06	4.69e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CAV1—malignant glioma	4.4e-06	4.67e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CG—malignant glioma	4.39e-06	4.67e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CB—malignant glioma	4.35e-06	4.63e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CD—malignant glioma	4.33e-06	4.6e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—malignant glioma	4.31e-06	4.58e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CG—malignant glioma	4.29e-06	4.55e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—malignant glioma	4.24e-06	4.5e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CA—malignant glioma	4.23e-06	4.49e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CA—malignant glioma	4.22e-06	4.49e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MYC—malignant glioma	4.2e-06	4.47e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.2e-06	4.46e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—malignant glioma	4.14e-06	4.4e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—malignant glioma	4.11e-06	4.37e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—malignant glioma	4.09e-06	4.34e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CG—malignant glioma	4.04e-06	4.29e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CG—malignant glioma	4.01e-06	4.26e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AKT1—malignant glioma	3.93e-06	4.18e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—malignant glioma	3.9e-06	4.14e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KRAS—malignant glioma	3.89e-06	4.13e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTP1—malignant glioma	3.87e-06	4.11e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—malignant glioma	3.87e-06	4.11e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CD—malignant glioma	3.86e-06	4.1e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTEN—malignant glioma	3.85e-06	4.09e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CB—malignant glioma	3.77e-06	4.01e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CD—malignant glioma	3.77e-06	4e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CAT—malignant glioma	3.77e-06	4e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTEN—malignant glioma	3.76e-06	4e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CAV1—malignant glioma	3.76e-06	3.99e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—malignant glioma	3.74e-06	3.97e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CA—malignant glioma	3.67e-06	3.9e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.59e-06	3.81e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CA—malignant glioma	3.57e-06	3.79e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NCOR1—malignant glioma	3.56e-06	3.78e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CD—malignant glioma	3.55e-06	3.77e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CD—malignant glioma	3.52e-06	3.74e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AKT1—malignant glioma	3.45e-06	3.67e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—malignant glioma	3.45e-06	3.67e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT1—malignant glioma	3.45e-06	3.67e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CG—malignant glioma	3.42e-06	3.64e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CB—malignant glioma	3.37e-06	3.58e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—malignant glioma	3.33e-06	3.54e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—malignant glioma	3.3e-06	3.51e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CB—malignant glioma	3.29e-06	3.49e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTEN—malignant glioma	3.26e-06	3.46e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—malignant glioma	3.25e-06	3.46e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.1e-06	3.29e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.07e-06	3.26e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—malignant glioma	3.07e-06	3.26e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—malignant glioma	3.04e-06	3.23e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CD—malignant glioma	3.01e-06	3.2e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AKT1—malignant glioma	3e-06	3.19e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT1—malignant glioma	2.92e-06	3.1e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTEN—malignant glioma	2.91e-06	3.09e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CAV1—malignant glioma	2.9e-06	3.08e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTEN—malignant glioma	2.84e-06	3.02e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CA—malignant glioma	2.72e-06	2.88e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTEN—malignant glioma	2.67e-06	2.84e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.65e-06	2.82e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTEN—malignant glioma	2.65e-06	2.82e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.64e-06	2.81e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.62e-06	2.79e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—malignant glioma	2.6e-06	2.76e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—malignant glioma	2.55e-06	2.71e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.32e-06	2.47e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CA—malignant glioma	2.3e-06	2.44e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTEN—malignant glioma	2.27e-06	2.41e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AKT1—malignant glioma	2.22e-06	2.36e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AKT1—malignant glioma	2.17e-06	2.3e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CA—malignant glioma	2.05e-06	2.18e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.02e-06	2.15e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—malignant glioma	2.01e-06	2.13e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CA—malignant glioma	2e-06	2.13e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.89e-06	2e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AKT1—malignant glioma	1.88e-06	2e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CA—malignant glioma	1.87e-06	1.99e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTEN—malignant glioma	1.75e-06	1.86e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AKT1—malignant glioma	1.68e-06	1.78e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AKT1—malignant glioma	1.64e-06	1.74e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.6e-06	1.7e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AKT1—malignant glioma	1.54e-06	1.64e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AKT1—malignant glioma	1.53e-06	1.62e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AKT1—malignant glioma	1.31e-06	1.39e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.23e-06	1.31e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AKT1—malignant glioma	1.01e-06	1.07e-05	CbGpPWpGaD
